Naratriptan Tablet
Product Images NDC 23155-054

9 FDA label images from Heritage Pharmaceuticals Inc. D/b/a Avet Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Naratriptan (NDC 23155-054). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Heritage Pharmaceuticals Inc. D/b/a Avet Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Stru Nara)

Image (Stru Nara)
Chemical structure of naratriptan hydrochloride, showing its molecular formula with aromatic rings and a piperidine moiety.*
FDA Label Image

Figa (Figa)

Figa (Figa)
A line graph depicting the estimated probability of response over time in minutes from the initial dose for naratriptan tablets 1 mg, 2.5 mg, and placebo. The y-axis shows the estimated probability of response as a percentage, and the x-axis shows time from 0 to 240 minutes. Data points are marked for placebo, naratriptan 1 mg, and naratriptan 2.5 mg, showing increasing response probabilities over time, with the 2.5 mg dose demonstrating the highest response rates at all measured time points.*
FDA Label Image

Figb (Figb)

Figb (Figb)
A line graph showing the estimated probability of remediation or rescue over 24 hours after an initial dose for naratriptan tablets at 1 mg and 2.5 mg versus placebo. The x-axis represents time in hours from initial dose, and the y-axis shows the probability from 0% to 100%. The placebo group shows the highest probability over time, followed by the 1 mg and 2.5 mg naratriptan groups.*
FDA Label Image
FDA Label Image
FDA Label Image

1 mg Foil (Nara 1 mg Blister)

1 mg Foil (Nara 1 mg Blister)
Naratriptan Tablet USP 1 mg packaging label for oral tablets, manufactured for Avet Pharmaceuticals Inc. Made in India. The label includes the product name, strength, barcode, National Drug Code (NDC) 23155-054-19, manufacturer details, and spaces for lot number and expiration date. The image shows multiple identical labels arranged in a sheet format for packaging.*
FDA Label Image

Naratriptan Tablets, Usp 2.5 mg, 9-unit Of Use Tablets (Nara 2.5 mg Carton)

Naratriptan Tablets, Usp 2.5 mg, 9-unit Of Use Tablets (Nara 2.5 mg Carton)
Naratriptan Tablets, USP 2.5 mg film-coated tablets label for a 9 unit-of-use blister pack. Manufactured by USV Private Limited and labeled for Avet Pharmaceuticals Inc. Storage instructions and usage directions are included. The packaging features tear and peel instructions to access individual tablets.*
FDA Label Image

Nara 1 mg Carton (Nara 1 mg Carton)

Nara 1 mg Carton (Nara 1 mg Carton)
Naratriptan Tablets, USP 1 mg oral tablets packaging label from Avet Pharmaceuticals Inc. The label shows 9 unit-of-use tablets, storage instructions at controlled room temperature, and manufacturer details including USV Private Limited in India. The label includes instructions for blister separation and tablet pocket exposure, and a barcode area along with a placeholder for pharmacy labeling.*
FDA Label Image

2.5 mg Foil (Nara 2.5 mg Blister)

2.5 mg Foil (Nara 2.5 mg Blister)
Naratriptan Tablet USP 2.5 mg packaging label showing multiple unit doses. The label includes the proprietary and generic name naratriptan, strength 2.5 mg, dosage form as tablet, and manufacturer information for Avet Pharmaceuticals Inc. The label also includes a barcode, NDC 23155-055-19, and markings for lot number and expiration date placeholders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.